CCL2 and atherosclerosis: FcαRI targeting using the anti-FcαRI antibody also reduced mitogen-activated protein kinase signaling and foam cell formation, leading to decreased interleukin (IL)-1b and monocyte chemoattractant protein (MCP)-1.<h4>Conclusions</h4>We demonstrated that targeting monovalent FcαRI suppresses atherosclerosis development.